Earlier this year, I told you about a new blood test—called Galleri—that could detect up to 50 different types of cancer. It’s currently under development by the healthcare company Grail, and uses cutting-edge sequencing technology to examine methyl groups on circulating DNA in blood samples.  And although it isn’t approved yet by the U.S. Food and Drug Administration (FDA), it is commercially available for about $950. […]